Press Releases

Durham, NC – Sept 4th, 2024 – EpiCypher®, a trailblazer in epigenetic research technologies, is pleased to announce an exclusive licensing agreement with Fred Hutch Cancer Center. This agreement grants EpiCypher access to pivotal intellectual property (IP) related to CUT&Tag technology, a revolutionary advancement in chromatin profiling developed by renowned scientist Dr. Steven Henikoff, a Fred Hutch molecular biologist and Howard Hughes Medical Institute Investigator.

The licensed IP encompasses three key areas of CUT&Tag technology poised to transform the field of epigenomics:

1. Cleavage Under Targeted Accessible Chromatin (CUTAC): This technology, detailed in patent application PCT/US2021/049944, offers unprecedented sensitivity for chromatin accessibility profiling. By mapping chromatin accessibility at transcription-coupled genomic features, such as promoters, enhancers, and gene bodies, CUTAC assays are data rich and generate far greater signal-to-noise compared to leading ATAC-seq methods. As a result, CUTAC provides a powerful new approach for low-input, single-cell, and spatial profiling studies. This IP also contains a streamlined “direct-to-PCR” method that mitigates sample clean-up following tagmentation, enabling assay automation and greatly simplifying single cell and spatial workflows.

2. Reverse Transcribe and Tagment (RT&Tag): Covered by patent application PCT/US2023/066213, this advancement enables profiling of chromatin-bound RNAs and associated RNA modifications with remarkable accuracy. This development has the potential to significantly deepen our understanding of RNA biology, including long noncoding RNAs, and its implications in disease.

3. CUT&Tag Compatibility with Formalin-Fixed Paraffin-Embedded Samples (CUT&Tag-FFPE) and biomarkers of hypertranscription in cancer: Described in patent applications PCT/US2024/031983 and 63/683,342, this strategy makes high-resolution CUT&Tag / CUTAC workflows compatible with FFPE samples, broadening epigenomic mapping applications for clinical research and precision medicine. To date, most FFPE profiling efforts have centered on transcriptome mapping, which are challenged by the poor quality and low recovery of RNA from FFPE tissues. As a DNA-based assay, CUT&Tag-FFPE generate high quality data that would be impossible to access using RNA-based assays, enabling access to archived FFPE samples. This approach has already been used to measure hypertranscription in several human cancers, highlighting its potential use to predict cancer aggressiveness.

By leveraging these cutting-edge technologies, EpiCypher will advance the capabilities of epigenomics research for biomarker discovery and drug development. The enhanced sensitivity and versatility of the licensed technologies enables researchers to conduct more precise and comprehensive studies and will accelerate development of emerging single cell and spatial CUT&Tag applications.

Dr. Martis Cowles, CBO of EpiCypher, expressed his enthusiasm about the new partnership: “Securing this exclusive licensing agreement with Fred Hutch Cancer Center represents another significant milestone for EpiCypher. We are excited to leverage these groundbreaking technologies to push the boundaries of epigenetics research and uncover novel insights that could transform our approach to biomedical research and precision medicine.”

EpiCypher plans to integrate these innovative strategies into its product and service offerings and is committed to supporting the research community with state-of-the-art tools for exploring complex biological questions.

For more information about EpiCypher Inc. and their breakthrough research technologies, please visit www.epicypher.com.

About EpiCypher Inc.

EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The Company is at the forefront of chromatin mapping technologies with the CUTANA® platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.

EpiCypher® and CUTANA® are registered trademarks of EpiCypher, Inc.

Media Contact: Ellen Weinzapfel PhD, info@epicypher.com

Partnership Contact: Martis W. Cowles PhD, martis@epicypher.com

Press Release on PR Newswire

AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays

New Haven, CT and Research Triangle Park, NC – January 23th 2024 – AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications. These assays will be developed on AtlasXomics’ DBiT-seq platform using CUT&Tag reagents and antibodies from EpiCypher, expanding the spatial ‘omics toolbox to histone post translational modifications (PTMs), transcription factors, and other chromatin regulators.

Spatial technologies enable joint analyses of cellular and molecular heterogeneity from intact tissues. The application of ultra-sensitive chromatin mapping assays, such as CUT&Tag, to spatial techniques is critical to the study of biological mechanisms in development and disease. CUT&Tag (Cleavage Under Targets and Tagmentation) was developed at Fred Hutchinson Cancer Center by Dr. Steven Henikoff (a molecular biologist and Howard Hughes Medical Institute Investigator) and commercialized by EpiCypher. This approach uses a fusion of Tn5 transposase, protein A, and protein G (pAG-Tn5) to cleave and add sequencing adapters at antibody-bound chromatin. Due to its remarkable sensitivity and adaptability, CUT&Tag has emerged as the leading platform for single-cell and spatial epigenomics applications.

AtlasXomics’ DBiT-seq (Deterministic Barcoding in Tissue for Spatial Omics Sequencing) platform was originally developed by Professor Rong Fan, Harold Hodgkinson Professor of Biomedical Engineering at Yale University. DBiT-seq utilizes a combination of microfluidics and next-generation sequencing for highresolution spatial profiling in tissues. DBiT-seq is rapidly gaining traction in the field, with successful applications in a wide range of tissues in over 50 laboratories worldwide. AtlasXomics has commercialized DBiT-seq for spatial ATAC-seq assays to map chromatin accessibility and is partnering with EpiCypher to introduce spatial CUT&Tag for profiling chromatin proteins, including histone PTMs and transcription factors.

“By seamlessly integrating molecular biology with histology, the DBiT-seq platform is revolutionizing epigenomics research," stated Colin Ng, Vice President of Business Development at AtlasXomics. “We have developed robust spatial assays that incorporate EpiCypher’s proprietary pAG-Tn5 enzyme and highefficiency antibodies to provide the optimal balance of sensitivity and specificity required for in-depth exploration of histone modifications and chromatin-associated proteins. Together, we will bring spatial CUT&Tag assays to market, including an expanded set of validated antibodies to provide customers with immediate access to diverse critical targets.”

EpiCypher holds key rights to CUT&Tag technology and a proprietary nucleosome-based approach to develop ultra-efficient antibodies for spatial and single cell CUT&Tag assays. “Spatial CUT&Tag depends on specific and efficient core reagents to capture more data per cell, which allows deeper biological insights,” said Dr. Martis Cowles, Chief Business Officer at EpiCypher. “We are very impressed with the DBiT-seq platform and look forward to working with AtlasXomics to maximize its impact on chromatin science and precision medicine.”

AtlasXomics and EpiCypher have focused initial development efforts on fresh frozen samples. Their long-term goal is to optimize spatial CUT&Tag for formalin-fixed paraffin-embedded (FFPE) samples, thereby greatly enhancing the versatility of these assays for clinical applications.

About EpiCypher - EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The Company is at the forefront of chromatin mapping technologies with the CUTANA™ platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.

About AtlasXomics - AtlasXomics, a 2020 Yale University spin-out, is commercializing a novel discovery platform that provides clinicians and researchers with unprecedented multi-omics tissue atlases. This innovative platform, called “Deterministic Barcoding in Tissue for spatial-omics sequencing” (DBiT-seq), leverages microfluidics and next generation sequencing (NGS) to create transformative multi-omics maps (proteomics, transcriptomics, and epigenomics) in tissue at cellular resolution, unlocking information about interactions between cells in localized neighborhoods. AtlasXomics is introducing groundbreaking spatial omics solutions to the market, starting with spatial epigenomics through its spatial CUT&Tag and spatial ATAC-seq assays.

EpiCypher® and CUTANA® are registered trademarks of EpiCypher, Inc.

AtlasXomics® is a registered trademark of AtlasXomics, Inc.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

Media Contact: Katelyn Noronha, AtlasXomics, Inc. info@atlasxomics.com

EpiCypher® announces automated CUT&RUN platform for high-throughput epigenomics

Research Triangle Park, NC – November 15th 2023 – EpiCypher announces the development of a fully automated CUT&RUN assay (autoCUT&RUN) for high-throughput mapping of chromatin features. Based on EpiCypher’s industry-leading CUTANA® CUT&RUN kits, this technology is a significant paradigm shift in epigenomic profiling, enabling scaled research that will advance therapeutic development and biomarker discovery.

CUT&RUN is a powerful approach to map the genomic distribution of chromatin-associated proteins, including histone modifications, transcription factors, and chromatin remodelers. This technique is a vast improvement over chromatin immunoprecipitation (ChIP), the historical gold-standard method for chromatin mapping. Compared to ChIP, CUT&RUN generates high resolution chromatin profiling data with improved signal-to-noise, but only requires a fraction of the cells and sequencing depth. CUT&RUN is highly amenable to assay automation, as it does not require cell lysis or chromatin digestion, which are impediments to assay scale-up in ChIP-based workflows.

EpiCypher has pioneered next-generation chromatin profiling technologies under the CUTANA® Collection, which includes the sister approaches CUT&RUN and CUT&Tag. At the core of these technologies is the integration of EpiCypher’s proprietary SNAP-CUTANA® nucleosomes, which are essential for well-controlled precision assays in support of reliable high-throughput studies.

“EpiCypher’s CUTANA® autoCUT&RUN platform provides epigenomics at a scale and cost that enables a higher resolution view and deeper insight to genome biology,” says Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “Our streamlined and standardized workflow can process thousands of CUT&RUN reactions per month, fundamentally transforming how chromatin mapping can be applied.”

EpiCypher developed the CUTANA® autoCUT&RUN solution to meet the rapidly growing demand for large scale applications, including therapeutic mechanism of action, drug dosing, cell identity fingerprinting, and biomarker discovery. EpiCypher will soon commercialize autoCUT&RUN as part of an end-to-end CUT&RUN assay service. In addition, the company will supply custom kit solutions to external labs, enabling the adoption of autoCUT&RUN to meet their scaling needs

“AutoCUT&RUN is the foundation of our end-to-end CUT&RUN assay services, providing a new standard for epigenomic profiling of research, pre-clinical and clinical samples,” says Dr. Martis W. Cowles, Chief Business Officer at EpiCypher. “We are encouraged by the overwhelmingly positive feedback from our early pharma partners who are leveraging autoCUT&RUN to advance their drug development programs.”

About EpiCypher – EpiCypher^® was created in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable epigenetics-focused drug development. The Company manufactures and sells the largest collection of defined “designer” nucleosomes (dNucs) on the market and offers a range of high-throughput nucleosome-based assays and services for chromatin research and drug development. EpiCypher is also at the cutting edge of chromatin mapping technologies with the recent launch of the CUTANA® platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. To enable these studies, EpiCypher sells best-in-class antibodies, nucleosome spike-in controls, supporting reagents, and library prep solutions, together providing all the necessary tools to go from cells to data. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.

EpiCypher® and CUTANA® are registered trademarks of EpiCypher, Inc.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

August 1, 2022: Carlsbad CA and Research Triangle Park NC – – CUT&Tag is a targeted transposition technique that allows high-resolution genomic mapping of histone modifications and chromatin-associated proteins through the precise insertion of DNA sequences into the genome using the Tn5 transposase enzyme.

EpiCypher and Active Motif each own or control patents covering complementary aspects of targeted transposition. Active Motif and EpiCypher have leveraged their respective IP to independently create successful genomic mapping tools that allow researchers to employ targeted transposition / CUT&Tag for advanced epigenomics research. Since 2020, there has been a patent dispute between the companies that culminated in patent infringement litigation.

EpiCypher and Active Motif have recently agreed to put their differences aside and today announced the signing of a global settlement ending the ongoing litigation, and a mutual crosslicensing agreement of their respective intellectual property. These developments will effectively resolve all outstanding legal issues between the two companies in the targeted transposition / CUT&Tag space.

The companies agreed that both Active Motif and EpiCypher’s IP are equally valid, and that both sets of IP are required to commercialize products and services that use technology involving targeted transposition techniques such as CUT&Tag. As part of the cross-licensing agreement, EpiCypher and Active Motif each agreed to provide to the other company a nonexclusive, royalty-bearing license to enable commercialization of products, kits, and services that use targeted Tn5 / CUT&Tag-based workflows. The companies also agreed to pool their IP and work together to sublicense targeted tagmentation technology for emerging fields of use, including single cell and spatial genomics assays. This places Active Motif and EpiCypher in a very strong position in the targeted transposition market.

"Today’s announcement is great for EpiCypher, Active Motif, and our collective customers", said Dr. Martis Cowles, Chief Business Officer of EpiCypher. "The Partnership between EpiCypher and Active Motif is a natural fit, and we look forward to working with Active Motif to maximize the impact of CUT&Tag technology on chromatin science and drug development".

"Targeted transposition technology has become increasingly important in simplifying the study of Protein-DNA interactions", said Ted DeFrank, President and CEO of Active Motif. Joe Fernandez, the Founder of Active Motif added, "We are pleased to be collaborating with EpiCypher to bring targeted transposition to the research and biotech communities."

About EpiCypher – EpiCypher^® is dedicated to developing transformative epigenetic solutions that advance the science of epigenetic regulation and improve human health. Most recently, EpiCypher has been at the leading edge of chromatin profiling technology with highly sensitive CUTANA™ epigenomic mapping assays for ChIC, CUT&RUN, and CUT&Tag. The Company also manufactures and sells the largest collection of defined "designer" nucleosomes (dNucs) on the market and offers a range of high-throughput nucleosome-based assays and services for chromatin research and drug development. For more information about EpiCypher, visit www.epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

About Active Motif – Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include scientists from academic and government institutions; biotechnology and pharmaceutical companies. Active Motif operates globally through its corporate headquarters in Carlsbad, California and offices in Shanghai China, Tokyo Japan and Waterloo Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com

EpiCypher^® partners with New England Biolabs® to codevelop CUT&RUN Library Prep Kit

Research Triangle Park, NC – February 08 2022 – – EpiCypher, Inc. today announced a partnership with New England Biolabs, Inc. (NEB^®) to codevelop a first-in-class library prep kit specifically optimized for best performance with their CUTANA^® CUT&RUN epigenomic assays. This CUTANA CUT&RUN Library Prep Kit is powered by NEBNext^® reagents from NEB, delivering a comprehensive and streamlined solution for preparation of CUT&RUN sequencing libraries.

CUT&RUN is rapidly replacing ChIP-seq as the leading chromatin mapping technology. In CUT&RUN, a fusion of protein A, protein G, and micrococcal nuclease (pAG-MNase) is used to selectively cleave antibody-labeled chromatin in situ, eliminating chromatin fragmentation and immunoprecipitation steps from ChIP to greatly simplify the assay workflow. Clipped fragments are easily isolated and purified, and the entire process is compatible with next-generation sequencing (NGS). This strategy virtually eliminates non-specific background and provides high quality mapping data using a fraction of the cell inputs, sequencing depth, and costs compared to ChIP-seq. Furthermore, the streamlined workflow has been fully automated for large-scale analyses, enabling the use of chromatin mapping for clinical research and personalized medicine.

A key step in CUT&RUN assays is the preparation of MNase-clipped fragments into sequencing-ready libraries. Existing library prep kits are designed for multi-purpose use and require supplemental reagents for specialized workflows, complicating assay development and increasing reaction costs. In addition, the general library prep protocols have been challenging to adapt for low yield CUT&RUN experiments. EpiCypher aims to address these concerns with a user-friendly and cost-effective library prep kit specifically developed for CUT&RUN.

Among leading library prep systems, EpiCypher found that NEBNext reagents from NEB consistently delivered the highest quality CUT&RUN libraries across multiple targets and DNA inputs.

"We worked with NEB to develop the first made-for-purpose library prep kit for CUT&RUN assays," said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. "The inclusion of NEBNext technology into our optimized workflow provides the highest quality reagents to fully realize the low-input capabilities of CUT&RUN."

The CUTANA CUT&RUN Library Prep Kit from EpiCypher provides all the reagents needed to efficiently generate sequencing libraries, including NEBNext reagents, DNA purification beads, and indexing primers.

"We have taken an all-inclusive approach to our kit design that takes the guesswork out of library prep," said Dr. Martis Cowles, Chief Business Officer at EpiCypher. "We look forward to additional collaborations with NEB, a life science company that is world-renowned for its innovative and high-quality products."

About EpiCypher – EpiCypher^® is dedicated to developing transformative epigenetic solutions that advance the science of epigenetic regulation and improve human health. Most recently, EpiCypher has been at the leading edge of chromatin profiling technology with highly sensitive CUTANA™ epigenomic mapping assays for ChIC, CUT&RUN, and CUT&Tag. The Company also manufactures and sells the largest collection of defined "designer" nucleosomes (dNucs) on the market and offers a range of high-throughput nucleosome-based assays and services for chromatin research and drug development. For more information about EpiCypher, visit www.epicypher.com.

About New England Biolabs – Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore, and the UK. For more information about New England Biolabs visit www.neb.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher^® announces co-exclusive licensing of foundational CUT&RUN / CUT&Tag IP

Research Triangle Park, NC – Dec 15 2021 – – EpiCypher, Inc. announces the co-exclusive licensing of CUT&RUN / CUT&Tag technology from Fred Hutchinson Cancer Research Center. This agreement strengthens EpiCypher’s intellectual property portfolio that includes CUT&RUN / CUT&Tag workflows for both Research Use Only (RUO) and diagnostics applications. EpiCypher is now firmly established as the leading commercial developer of CUT&RUN / CUT&Tag reagents, kits, and assay services. Under this co-exclusive licensing partnership, EpiCypher will expand their CUTANA CUT&RUN and CUT&Tag product lines and explore new opportunities that increase access to these transformative epigenomic technologies.

CUT&RUN and CUT&Tag are rapidly replacing ChIP-seq as the preferred method to study histone post-translational modifications (PTMs) and chromatin-associated proteins. The new approaches require 10-fold fewer sequencing reads and can employ ultra-low cellular inputs, including single-cell analyses. Importantly, these assays are automation-compatible, thus enabling epigenomics analyses on scales that support drug development and clinical research.

CUT&RUN and CUT&Tag were created by the laboratory of Dr. Steven Henikoff, a Fred Hutch molecular biologist and Howard Hughes Medical Institute Investigator.

"EpiCypher’s CUTANA platform is changing the way researchers approach genomic mapping studies – especially for drug development," said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. "This foundational IP gives us the support to build next-generation assays that further improve assay sensitivity, throughput and cost.""

This new co-exclusive licensing agreement strengthens EpiCypher’s existing patent portfolio, which includes fundamental IP covering DNA-barcoded nucleosomes and their use for antibody validation and quantitative sample normalization. EpiCypher is committed to leveraging this IP to revolutionize how researchers use epigenomics for drug development and clinical research.

"We look forward to exploring commercial partnership opportunities that expand global access to our technologies," said Dr. Martis Cowles, Chief Business Officer at EpiCypher. "With our passion for innovation, EpiCypher is dedicated to delivering the full potential of CUT&RUN and CUT&Tag technology to accelerate drug development and improve human health.""

About EpiCypher – Founded in 2012, EpiCypher^® was created in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable epigenetics-focused drug development. The Company brings transformative technologies to market and offers superior products and assay services to researchers worldwide. EpiCypher manufactures and sells fully defined “designer” nucleosomes (dNucs), which are integrated to the SNAP-ChIP^® product family for quantitative genomic mapping applications, and the dCypher^® assay platform to dissect the capability of epigenetic regulators in their physiological context. Currently, EpiCypher is at the cutting edge of chromatin mapping technologies with the recent launch of the CUTANA^® platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. These provide major advantages compared to ChIP-seq, delivering high quality epigenomic data with an ease of adoption and price accessible to a broad range of researchers.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher^® announces Southeast Asian Distribution Channel

Research Triangle Park, NC – 29 March 2021 – – Leading epigenetics company, EpiCypher Inc., has added Biomed Global to its world-wide distribution network to strategically address southeast Asia’s demand for the Company’s products and services. EpiCypher products are available to 27 countries outside of the United States, now including Singapore and Malaysia.

For over 20 years, Biomed Diagnostics Pte Ltd – Biomed Global has been a total solution provider in the biomedical and life sciences industry and is driven by their passion to make a difference to doctors, patients, researchers and academics.

“We’re excited to extend distribution rights to Biomed Global. Biomed is a well-established and highly recognized company servicing the life sciences industry in Malaysia and Singapore,” said Dr. Jim Bone, President, EpiCypher. “We’re confident that their network, local expertise and product knowledge will increase our presence and participation in this important regional market.”

Biomed Global (biomed-global.com) represents some of the world's renowned brands known for their products in biomedical sciences, microbiology, molecular biology, genetics testing and imaging systems.

About EpiCypher – EpiCypher was founded in 2012 in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable epigenetics-focused drug development. The Company develops transformative technologies and offers superior products and discovery services to researchers worldwide. EpiCypher manufactures and sells recombinant “designer” modified nucleosomes (dNucs), including the SNAP-ChIP® product family for quantitative ChIP applications, as well as recombinant histone binding proteins, peptides and antibodies. They also offer a broad range of custom substrate manufacturing and assay development services. Most recently, EpiCypher has been at the leading edge of chromatin mapping technology improvements with the recent launch of highly sensitive epigenomic mapping CUTANA™ assays for ChIC, CUT&RUN, and CUT&Tag.

For more information about EpiCypher, visit EpiCypher.com.

To see a complete list of EpiCypher International Distributors, visit https://www.epicypher.com/global-distributors/.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher^® announces the launch of CUTANA™ (ChIC / CUT&RUN / CUT&Tag) for next-generation genomic mapping studies

Research Triangle Park, NC – July 23 2019 – EpiCypher, Inc. announces the commercial licensing of ChIC (University of Geneva) and CUT&RUN / CUT&Tag (Fred Hutchinson Cancer Research Center) technologies. These breakthrough tools reflect EpiCypher’s growing influence and expertise in epigenetics, and expand our product portfolio to include ultra-sensitive / robust chromatin profiling reagents, kits and services. Of note, this announcement precedes the August 2019 release of EpiCypher’s Protein A-Protein G-Micrococcal Nuclease (pAG-MNase), the critical reagent for ChIC / CUT&RUN workflows. In the coming months, EpiCypher will offer additional CUT&RUN / CUT&Tag reagents, user-friendly kits and end-to-end services under the CUTANA™ platform.

ChIC (Chromatin ImmunoCleavage) was developed by Dr. Ulrich K. Laemmli’s laboratory at the University of Geneva and centered on the fusion of Protein A to Micrococcal Nuclease (pA-MNase) for the selective cleavage of antibody-bound chromatin. The CUT&RUN (Cleavage Under Targets & Release Using Nuclease) and CUT&Tag (Cleavage Under Targets & Tagmentation) methods were developed by the group of Dr. Steven Henikoff, a Howard Hughes Medical Institute investigator at Fred Hutchinson Cancer Research Center. CUT&RUN builds on ChIC by immobilizing cells / nuclei on solid support, which enables efficient isolation of pA-MNase cleaved DNA fragments from solution. Dr. Henikoff’s recently published CUT&Tag is a modification of CUT&RUN, which uses Protein A fused to a hyperactive transposase loaded with sequencing adaptors (pA-Tn5) to expedite sample processing and sequencing library preparation.

ChIC and CUT&RUN / CUT&Tag strategies have revolutionized the study of histone post-translational modifications (PTMs) and chromatin-associated proteins. Compared to ChIP-seq, the leading approach for genome-wide mapping of histone PTMs and chromatin-associated proteins, CUT&RUN / CUT&Tag require substantially fewer cells (including single cell analysis from bulk samples by CUT&Tag), are compatible with low sequencing depths, and have markedly improved [signal : noise]. EpiCypher’s optimized pAG-MNase is the first-in-class commercial product for CUT&RUN assays, accelerating sample processing and allowing a substantial reduction in sequencing depth without any sacrifice in data quality. This reagent enables the unprecedented use of benchtop sequencers (e.g. Illumina^® MiniSeq or MiSeq) to directly generate genomic mapping profiles, making the approach widely accessible to chromatin scientists and dramatically improving experimental throughput.

To further address the ongoing crisis of histone PTM antibody specificity, EpiCypher has leveraged the K-AcylStat SNAP-ChIP panel to identify and launch a new line of SNAP-ChIP certified antibodies, targeting many common lysine-acyl PTMs, including H3K9ac. Using K-AcylStat, EpiCypher is able to identify superlative reagents for studying these modifications using ChIP.

“ChIC and CUT&RUN technologies directly address several pressing and unmet needs in the chromatin field,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “CUTANA will enable scientists to profile more samples, at greater resolution, in less time, and at reduced cost. These capability gains will fundamentally change how the field approaches genome-wide chromatin mapping studies.”

EpiCypher is a global leader in enabling genome-wide chromatin analyses, best exemplified by the recent development and commercialization of SNAP-ChIP^®, a transformative spike-in reagent for ChIP assay quantification and antibody validation. EpiCypher is currently transferring this spike-in technology to CUT&RUN / CUT&Tag, which will allow in situ antibody specificity testing and the quantitative normalization of sequencing data. Moving forward, EpiCypher will continue to build relationships with leading scientists in academia and industry to develop innovative tools that will accelerate chromatin research and ultimately improve human health.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher^® is a biotechnology company developing transformative technologies to researchers and drug developers worldwide. EpiCypher manufactures and sells a series of products and assay platforms that use recombinant “designer” modified nucleosomes (dNucs), including the SNAP-ChIP^® product family for quantitative ChIP applications and the EpiDyne^® product family for nucleosome remodeling assays, as well as recombinant histone binding proteins and enzymes, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher^® launches K-AcylStat™ SNAP-ChIP^® spike-in panels and certified antibodies, expanding the application of SNAP-ChIP^® technology

Research Triangle Park, NC – 16 May 2019 – EpiCypher, Inc. announces the availability of the K-AcylStat SNAP-ChIP spike-in panel, increasing the diversity of histone post-translational modifications (PTMs) accessible via EpiCypher’s proprietary SNAP-ChIP technology and providing unparalleled flexibility in controlling ChIP experiments.

SNAP-ChIP uses DNA-barcoded recombinant designer nucleosomes (dNucs), which replicate endogenous nucleosomes, as spike-in controls to profile antibody specificity and binding efficiency in ChIP. EpiCypher’s 2018 Molecular Cell paper (Shah et al. 2018, 72:162-177) demonstrated the superior capabilities of SNAP-ChIP in determining antibody discrimination, compared to the industry-wide standard histone peptide arrays. This paper also revealed that nearly 80% of commercial antibodies fail to specifically recognize the desired PTM in a nucleosome context.

EpiCypher’s initial SNAP-ChIP spike-in panels focused on histone lysine methylation (K-MetStat) and oncogenic histone mutations (OncoStat). The new K-AcylStat panel enables the application of SNAP-ChIP to a diverse set of histone lysine acylation PTMs, and includes 22 dNucs carrying distinct acetyl, crotonyl, and butyryl PTMs, as well as an unmodified nucleosome control. In total, EpiCypher’s SNAP-ChIP panels represent more than 45 PTMs and histone variants, providing access to the most widely studied and biologically relevant histone PTMs in the field.

To further address the ongoing crisis of histone PTM antibody specificity, EpiCypher has leveraged the K-AcylStat SNAP-ChIP panel to identify and launch a new line of SNAP-ChIP certified antibodies, targeting many common lysine-acyl PTMs, including H3K9ac. Using K-AcylStat, EpiCypher is able to identify superlative reagents for studying these modifications using ChIP.

“The release of the K-AcylStat spike in panel and corresponding SNAP-ChIP certified antibodies provides consistent and reliable reagents for the field, which will improve the quality of chromatin research,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher^® is a biotechnology company developing transformative technologies to researchers and drug developers worldwide. EpiCypher manufactures and sells a series of products and assay platforms that use recombinant “designer” modified nucleosomes (dNucs), including the SNAP-ChIP^® product family for quantitative ChIP applications and the EpiDyne^® product family for nucleosome remodeling assays, as well as recombinant histone binding proteins and enzymes, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

EpiCypher^® signs agreement with Thermo FIsher Scientific to deliver best-in-class ChIP-grade antibodies specific for histone PTMs

Research Triangle Park, NC and Carlsbad, CA – 24 April 2019 – EpiCypher^®, a pioneer in the manufacture of functionalized recombinant nucleosomes, announced today the signing of an agreement with Thermo Fisher Scientific, the world leader in servicing science, to provide co-exclusive use of EpiCypher’s SNAP-ChIP^® technology. SNAP-ChIP^®(Sample Normalization and Antibody Profiling for Chromatin Immunoprecipitation) is a proprietary spike-in control developed by EpiCypher that can be added to Chromatin immunoprecipitation (ChIP) assays for quantitative sample normalization and to monitor the specificity of antibodies. SNAP-ChIP incorporates DNA-barcoded recombinant modified nucleosomes to make ChIP truly quantitative, and is currently the only tool available for accurately identifying ChIP-grade histone PTM-specific antibodies.

“A major goal of this partnership is to fix the antibody specificity problem that has long plagued ChIP, and Thermo Fisher is the ideal partner to leverage SNAP-ChIP technology for the development of highly specific ChIP-validated antibodies,” said EpiCypher President Jim Bone.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher^® is a biotechnology company developing innovative and transformative technologies to researchers and drug developers worldwide. EpiCypher pioneered the manufacture of modified recombinant nucleosome, and uses this expertise to create products and assay platforms incorporating modified nucleosomes (dNucs). These include the SNAP-ChIP^® product family for quantitative ChIP applications and the EpiDyne^® product family for nucleosome remodeling assays. EpiCypher sells the best fit-for-purpose SNAP-ChIP-validated antibodies, and offers a broad range of custom nucleosome substrate manufacturing and assay development services.

EpiCypher^® launches dCypher™: A service to discover novel chromatin binding interactions

Research Triangle Park, NC - 24 October 2018 – EpiCypher, Inc. has released dCypher, a revolutionary service leveraging EpiCypher’s expertise in post-translationally modified recombinant designer nucleosomes (dNucs) and histone peptides to deliver highly sensitive and fully customizable assays for the rapid interrogation of chromatin binding interactions.

Academic, pharmaceutical, and clinical research put the association between chromatin and human disease beyond question. Despite this fundamental understanding, there are few discovery-based tools available for epigenetics-focused drug and therapeutic development.

Part of the problem is the vast diversity of the epigenome. With >100 histone post-translational modifications (PTMs) identified to date, many of these occurring in combination, it is difficult to thoroughly characterize the binding specificity of novel chromatin-interacting proteins with existing technologies. Yet, understanding how putative chromatin interactors deal with this expanse of histone PTMs is essential to progress research and drug discovery efforts.

Histone peptide arrays have been the gold standard for histone PTM-protein interaction screens, but they are far from optimal. Due to their low sensitivity and variable signal, they require high amounts of purified protein to identify binding interactions. Even then, many binding targets with potential disease relevance have proven inaccessible to the approach.

dCypher now offers a unique solution to this problem, providing improved signal to noise with up to 2,000-fold less input material vs. peptide array, and giving results from low-affinity binders with unprecedented efficiency. dCypher customers will have access to EpiCypher’s library of ~300 histone peptides and ~75 dNucs, enabling customized analysis of interactions between chromatin readers and histone PTMs. Thus, dCypher provides scientists an innovative service that produces high-confidence data in a field often limited by reagents with low sensitivity and accuracy.

‘dCypher positions EpiCypher at the forefront of epigenetics technology. It is truly enabling and integrates exquisitely sensitive, accurate and rapid screening technologies for chromatin-targeted drug discovery,’ said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. As dCypher is a fully customizable platform, any number and combination of PTMs may be screened in any context. This service will be of particular use for target identification, validation studies, and identifying optimal substrates for drug inhibitor screens.

About EpiCypher -A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a biotechnology company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher manufactures and sells recombinant “designer” modified nucleosomes (dNucs), including the SNAP-ChIP^® product family for quantitative ChIP applications, as well as recombinant histone binding proteins, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

For more information about dCypher™ services, visit EpiCypher.com/services/dcypher-assay-services-for-novel-chromatin-interactions For more information about EpiCypher, visit EpiCypher.com

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher SNAP-ChIP^® technology poised to transform market for histone PTM antibodies

Research Triangle Park, NC - 4 October 2018 – A recently published report in Molecular Cell validates the use of EpiCypher’s proprietary SNAP-ChIP technology for profiling antibody specificity and sensitivity. SNAP-ChIP^® (Sample Normalization and Antibody Profiling for Chromatin Immunoprecipitation) utilizes pools of DNA-barcoded designer modified nucleosomes (dNucs) as quantitative spike-in controls for ChIP-Seq normalization and antibody specificity testing.

Using this new approach, many commonly used ‘ChIP-grade’ antibodies failed due to significant cross-reactivity with other histone PTMs, including some of those recommended by the ENCODE consortium. These results highlight the need for internal controls to monitor antibody performance in each ChIP experiment, and position SNAP-ChIP as the new gold standard for antibody validation in ChIP.

‘The results are striking and will have an immediate impact on the field’, said Dr. Michael- Christopher Keogh, Chief Scientific Officer at EpiCypher and a corresponding author on the study. ‘Our ongoing investigations demonstrate that ChIP-incapability, despite what their datasheets promise, is a widespread issue for histone PTM antibodies, and highlights a critical need for re-evaluating these reagents’.

EpiCypher is using SNAP-ChIP^® technology to screen hundreds of commercially available antibodies to identify those with best-in-class performance. These “SNAP-ChIP^® certified antibodies” are available now from EpiCypher and their use will be essential to provide a renewed confidence in data generated using ChIP.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher manufactures and sells recombinant “designer” modified nucleosomes (dNucs), including the EpiDyne™ family of substrates for nucleosome remodeling assays, as well as recombinant histone binding proteins, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

For more information about SNAP-ChIP^®, visit EpiCypher.com/products/nucleosomes/snap-chip-spike-ins For more information about SNAP-ChIP^® certified antibodies, visit EpiCypher.com/snap-chip-certified-antibodies/

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Launches SNAP-ChIP Product Family: Now Enabling Normalized Chromatin IP Experiments

Research Triangle Park, NC - 22 September 2017 – EpiCypher, Inc. has released SNAP-ChIP (Sample Normalization and Antibody Profiling for Chromatin Immunoprecipitation), a breakthrough product family that will dramatically improve researchers’ ability to normalize ChIP experiments. SNAP-ChIP utilizes EpiCypher’s proprietary DNA barcoded recombinant designer nucleosomes (dNucs) as next-generation spike-ins for ChIP. With SNAP-ChIP, researchers now have the ability to both normalize samples across experiments (enabling broad collaboration throughout the scientific community, an the generate detailed data pertaining to antibody specificity and cross-reactivity.

The first offering in the SNAP-ChIP family, the SNAP-ChIP K-MetStat panel (lysine-methylation status panel), is comprised of 16 uniquely modified dNucs carrying disease-relevant lysine methylation modifications on histones H3 and H4. Each modification site in this pool (H3K4, H3K9, H3K27, H3K36, H4K20) is represented by all lysine methylation states (i.e. me0, me1, me2, and me3). “For the first time, scientists can both monitor technical variability and measure antibody specificity in the same experiment. This has not been possible with any other spike-in product or approach currently available,” states EpiCypher’s Chief Scientific Officer, Michael Keogh, PhD. Keogh further adds “The beauty of the SNAP-ChIP product line is that it fits seamlessly into existing ChIP workflows, allowing the epigenetics community immediate access to this breakthrough. In fact, we have already contracted with a number of antibody development companies to use our SNAP-ChIP K-MetStat Panel to directly analyze the specificity of antibodies in their portfolios in a ChIP setting.”

Numerous additional modification-specific SNAP-ChIP dNuc panels are currently in development (e.g. arginine methylation, lysine acylation, etc.) and are slated for release in early 2018.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher manufactures and sells recombinant “designer” modified nucleosomes (dNucs), including the EpiDyne™ family of substrates for nucleosome remodeling assays, as well as recombinant histone binding proteins, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

For more information about SNAP-ChIP, visit EpiCypher.com/products/nucleosomes/snap-chip-spike-ins For more information about EpiCypher, visit EpiCypher.com

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Named Best University Startup by United States Congress

Research Triangle Park, NC - 7 September 2016. EpiCypher today announced its designation as Best University Startup by the National Council of Entrepreneurial Tech Transfer (NCET2), a group designated by the 114th United States Congress.  EpiCypher will present to US Congress, investors and corporate partners at the inaugural University Startups “Demo Day” at the National Press Club in Washington, DC on September 20, 2016.

There are over 4,800 active university start-ups in the United States today.  Those recognized as the Best University Startups 2016 are among the most exciting early-stage companies originating from the country's top tier universities.

"We are delighted and honored to be named Best University StartUp at the inaugural Demo Day 2016 in Washington DC. EpiCypher has been built from the dedication and focus of our employees & Founders, support from our customers, and funding from Americas’ Seed Fund, the NIH SBIR program,” said Jim Bone, President, EpiCypher. “Our future is bright for both job creation and the rapid launch of new products and services. The fusion of these key elements enable us to realize our ultimate mission of saving human lives.

EpiCypher is a spinout from The University of North Carolina at Chapel Hill.  Scientific Founders Drs. Brian Strahl, Vice-Chair (Department of Biochemistry & Biophysics at UNC-CH), Mark Bedford, Professor (MD Anderson Cancer Center), and Or Gozani, Professor (Stanford University) established the original scientific vision for the Company that remains today. "To lead the world in the 21st Century, our nation must have a sustained commitment to education, scientific research, and startups," says Tony Stanco, NCET2 executive director, "and American universities are uniquely positioned to deliver on all three to ensure the U.S. continues to lead socially and economically in this century, as it did in the last."

EpiCypher Snaphot:

• 85 blue-chip customers
• 18 full-time employees; 80% with advanced degrees
• The only UNC-Chapel Hill spinout that is cash-flow positive (circa 2012)
• Doubled revenue annually for the past 3 years

About EpiCypher. EpiCypher is pioneering the science of epigenetics. Epigenetics is the conjunction of ‘epi’, Latin for above, and genetics.  Epigenetics is an essential dimension of personalized medicine, representing additional biological coding beyond genetics that regulates protein expression.   EpiCypher has brought necessary products to market, including the first biochemically pure recombinant nucleosome and the first industry-developed designer nucleosomes.  In addition, EpiCypher is developing the first reliable epigenetics biomarker measurement system for use in research and clinical applications.  EpiCypher has over 85 blue-chip customers, 18 people, and is cash-flow positive. For more information visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Announces Key Appointments to Bolster Sales and Product Development Expansion of management team deepens scientific capability, client service and support.

Research Triangle Park, NC – 16 February 2016 – EpiCypher Inc., a global provider of epigenetics research products and services, today announced the appointment of two talented individuals to its management team in response to new R&D directives and an increased share of the epigenetics products market.

Danielle Mahon.  Director, Scientific Sales Ms. Mahon brings 21 years of successful sales experience to EpiCypher including the last 10 years in the life science arena managing capital equipment and consumable sales in pharmaceutical, biotechnology and academic settings. During this time Ms. Mahon worked for industry leaders including Eppendorf, Mettler Toledo and ThermoFisher Scientific. She has a strong track record with key account development and management. She holds a Bachelors of Science in Management from Rutgers University.

Michael-Christopher Keogh, Ph.D. Director, Markets and Application Development Dr. Keogh earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.

“The addition of these highly talented and experienced individuals to the EpiCypher team deepens our capability to deliver innovative and practical solutions to our customer base.  Danielle brings world-class success in delivering global customer success and distributor engagement.  In her role, Danielle will develop and implement our commercial strategy,” said Jim Bone, President and co-founder of EpiCypher.  “Michael brings exceptional scientific experience with an outstanding publication track record.  His external focus on application development will significantly benefit our customer base.  In his role, Michael will bring forward EpiCypher’s deep scientific expertise in driving development and adoption of our innovative product portfolio”.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Expands Global Distribution NetworkCompany responds to increased global demand for products and services.

Research Triangle Park, NC  - 16 February 2016 - EpiCypher Inc. added five strategic distributors in 2015 responding to increased global demand for the Company’s products and services. A total of 16 companies now represent EpiCypher outside of the United States, including nine in Europe.

EpiCypher announced the following distributors after the significant training and support from EpiCypher to enable success in their local markets.

North America: MJS BioLynx, Inc - Brockville, Ontario, Canada (biolynx.ca)

Asia: ABclonal Biotechnology Co., Ltd - Wuhan, Hubei, P.R.China (abclonal.com) Bioinborn Scientific, Inc - Wuhan City, China P.C. (bioinborn.com) Cistron Biolab - Kattupakkam, Chennai, India (cistronbiolab.com) KOMA BIOTECH - Seoul, South Korea (komabiotech.com)

“The addition of these highly reputable companies to the EpiCypher distributor portfolio will broaden our sales capacity in established international markets”, said Danielle Mahon, Director of Scientific Sales, EpiCypher. “The end-user will benefit from local customer service and expedited shipping of our products.”

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Announces EpiCypher2016 as Major Epigenetics Conference PerkinElmer among sponsors of EpiCypher 2016.

Research Triangle Park, NC - 10 February 2016 – EpiCypher, Inc. has announced EpiCypher2016, a conference focused on Biological and Chemical Frontiers in Epigenetics, to be held April 20-23 in San Juan, Puerto Rico. The conference is being organized by Drs. Brian Strahl, University of North Carolina at Chapel Hill; Or Gozani, Stanford University; and Mark Bedford, Univ. Texas MD Anderson Cancer Center.

The four-day conference at the luxury oceanfront Caribe Hilton in San Juan will highlight recent breakthroughs in epigenetics and chromatin research and will foster the collaboration and exchange of scientific expertise and knowledge in one of the most vibrant areas of life sciences. Through scientific presentations, a wide spectrum of topics in epigenetics and chromatin biology will be explored. The conference has over 25 confirmed speakers with a lineup of luminaries and thought leaders from industry and academic centers. PerkinElmer, Inc. is a sponsor for the event.

“EpiCypher2016 represents a significant commitment to the field and the thought leaders that are shaping the future of epigenetics. We’re delighted to have PerkinElmer as part of this inaugural event in light of our recent collaboration yielding a panel of bromodomain binding assays utilizing their highly sensitive AlphaLISA^® detection technology.” said Jim Bone, President and co-founder of EpiCypher. “We look forward to noteworthy announcements and scientific findings from EpiCypher2016.”

EpiCypher2016 will feature keynote addresses by Dr. C. David Allis and Dr. Yang Shi. Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Dr. Shi is the Merton Bernfield Professor of Neonatology at Boston Children’s Hospital / Harvard Medical School.

The plenary session talks will cover broad aspects of epigenetics and chromatin biology, ranging from basic molecular mechanisms to therapeutic efforts. There will be discussions around the elucidation of novel mechanisms, new tools, and other breaking topics in epigenetics and chromatin research.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher™ Introduces Nucleosome Product Line Complete product line of nucleosomes allows researchers to identify authentic hits on a more consistent basis

Research Triangle Park, N.C. –July 9, 2015 – EpiCypher today announced the introduction of a complete line of purified and fully recombinant nucleosomes for use in epigenetic and chromatin biology research. Nucleosomes are the most physiologically relevant substrates for chromatin modifying enzymes and are ideal for protein binding and inhibitor screening assays in drug discovery research. EpiCypher leads the industry in both innovation and quality of nucleosome-based products.

The most compelling feature of nucleosomes from EpiCypher is the superior purity of the product (>98%), allowing more focus on optimizing libraries and reaching successful hits on a more consistent basis. “EpiCypher offers the highest quality and most highly validated nucleosome products currently available. Epigenetic proteins and enzymes are becoming increasingly important targets for therapeutic intervention. The incorporation of EpiCypher’s nucleosomes into drug development research allows researchers to identify authentic hits on a more consistent basis, as well as reducing the amount of substrate required,” states EpiCypher President Jim Bone. The stringent quality control standards utilized by EpiCypher ensure reliable and repeatable results every time, negligible lot-to-lot variation and a reduced risk of false positives or false negatives.

About EpiCypher Pioneering the Science of Epigenetics™ A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

Regional Entrepreneurial connector, Blackstone Entrepreneurs Network, expands in the Region with RTP Frontier space

The Blackstone Entrepreneurs Network announced its newest meeting space in The Frontier building in RTP. The Frontier, operated by the Research Triangle Foundation, is quickly becoming a hot-spot in the entrepreneurial community by providing a collaborative work environment. The move, made possible by the Research Triangle Foundation, enables the Blackstone Entrepreneurs-in-Residence (EIRs) and Companies easier access to each other and adds a central meeting place. The move will help The Network in its mission to coach high-growth companies by providing a location in the heart of the region.

The Blackstone Entrepreneurs Network was created in 2011 by a coalition of four universities (Duke, NC Central, NC State, and UNC-Chapel Hill) in conjunction with CED, and funded by the Blackstone Charitable Foundation.

“It is fitting to add this new location in RTP to our program,” says Judith Cone, Coalition Managing Partner. “Since its founding, the RTP has been a place where academic institutions and the private sector come together to build the state’s economy. Once again the universities and private sector, through this program and this location, are collaborating toward that same goal. Unlike much of the past work that focused on recruiting industry, this program focuses on growing our own companies led by North Carolina’s proven entrepreneurs.”

According to Peter Bourne a Blackstone EIR, opening a location in RTP will enhance the program’s effectiveness. “This move will bring Network Entrepreneurs-in-Residence and Client companies into the center of the RTP startup community,” says Bourne. “The critical mass of companies and startups, and its proximity to the Triangle’s four universities, makes it an excellent strategic location.” This location will give Network Companies headquartered in Raleigh, Durham and Chapel Hill easy access to meeting space. “Having access to Research Triangle Park is a huge advantage for us,” says Jim Bone, President and co-founder of EpiCypher, a Mentored Network company. “We’re able to meet with our Blackstone EIRs at the Park and make connections that would not be possible sitting in our office.”

The Frontier is the first project in the new Park Center development and is designed as an open community space for those located in and aroud the Research Triangle Park. The Frontier provides free work and meeting space, as well as competitive lease rates for private offices throughout the 142,000 square foot building.

“We are thrilled to have Blackstone Entrepreneurs Network in The Frontier,” said RTP Chief Operating Officer Mason Ailstock. “The Network is an amazing resource for entrepreneurs and startups in the region, and their presence is a valuable addition to our growing list of tenants. We’re excited for the many opportunities this partnership will bring RTP,” said Ailstock.

About Blackstone Entrepreneurs Network: The Blackstone Entrepreneurs Network mission is to unlock the tremendous economic potential of startups from the universities and the community in the RTP region and the State of North Carolina. Proven, serial entrepreneurs (EIRs), who have themselves raised significant venture capital, work together as a cohesive group to provide intensive coaching to promising entrepreneurial teams. Their goal is to help the next generation of entrepreneurial ventures raise the capital necessary to reach their next stages of growth. This is a philanthropic endeavor free of charge to those accepted in the program and takes no equity in the companies it coaches. To learn more, visit www.blackstoneentrepreneursnetwork.org.

About The Research Triangle Park The Research Triangle Foundation of North Carolina serves the Research Triangle Park, a bellwether institution that was once referred to by Governor Luther Hodges as the “heart and hope of North Carolina.” Situated centrally among Duke University, North Carolina State University and the University of North Carolina at Chapel Hill, RTP contains 7,000 acres, 50,000+ employees, and over 200 companies, including Avaya, Cisco, Credit Suisse, IBM, NetApp, RTI International and Syngenta. RTP is also home to The Lab, an affordable incubation space for entrepreneurs and startups.

About The Frontier Located in the heart of RTP’s Park Center development, The Frontier is an open collaboration destination that can be used by anyone in the community for a variety of reasons. It’s connected to lightning fast internet, has free Counter Culture coffee for all visitors and plays host to weekly events sponsored by The Research Triangle Park. There’s never any shortage of activity, and the community at-large is invited to use the space as if it was their very own. Find out more at rtp.org/thefrontier.

About EpiCypher Pioneering the Science of Epigenetics™ A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Launches New Website and New Identity Users find extensive resources, an enhanced user experience, and rich content at www.epicypher.com.

Research Triangle Park, N.C. –February 17, 2015 – EpiCypher today announced the launch of a new version of www.epicypher.com. Key benefits of the new site include a cleaner & more attractive design, a more engaging user experience with enhanced search, improved navigation and deeper e-commerce capabilities. The new online presence provides fast and intuitive access to the company’s deep product lines as well as extensive resources for scientists with demanding needs in epigenetic and chromatin biology.

The website was created with the user experience firmly in mind. For mobile applications in particular, the site delivers an excellent user experience using the latest technology. The site’s refreshed & simplified look, enhanced content, improved search functionality, and optimization for mobile devices allows visitors to immerse themselves in the depth of EpiCyphers capability.

Our mission is to connect scientist and researchers to the latest in epigenetic tools, products and services. “The science-centric design of the site provides an innovative platform for researchers that will boost the applicability of our products and services to researchers needs, and thus further their discoveries,” says EpiCypher president and co-founder, Jim Bone.

About EpiCypher Pioneering the Science of Epigenetics™

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher™ Awards Five Epigenetic Research GrantsEpiCypher’s First Annual Grant Program Funds 5 Histone Modification Research Projects

Chapel Hill, N.C. –October 7, 2014 – EpiCypher announces the award of five grants for Histone Peptide Array Screening Services to researchers at Indiana University, Memorial Sloan Kettering Cancer Center, The University of Florida, The University of Montreal and The Structural Genomics Consortium as part of their first annual grant program in support of chromatin biology and epigenetics research. The scientific founders of EpiCypher reviewed each grant application and selected the winners, each of whom will receive histone modification screening services employing EpiCypher’s world-class EpiTitan™ Histone Peptide Arrays, along with a statistical analysis of their protein’s or antibody’s histone modification binding profile.

The grantees are: Levi Blazer, Ph.D., Structural Genomics Consortium; El Bachir Affar, Ph.D., University of Montreal; Omar Abdel-Wahab, M.D., Memorial Sloan-Kettering Cancer Center; Feng-Chun Yang, Ph.D., Indiana University School of Medicine; and Daiqing Liao, Ph.D, University of Florida. The grant recipients and their respective organizations will work individually but collaboratively with EpiCypher’s scientific team to help answer each project’s fundamental biological question.

EpiCypher is dedicated to giving researchers access to the highest quality, most productive approaches for more meaningful investigations into chromatin biology and epigenetics research. “We look forward to introducing these winners to the many benefits of our transformative products and incorporating them into their research so they can experience their advantages to chromatin research first hand,” says EpiCypher President and co-founder Jim Bone.

About EpiCypher Pioneering the Science of Epigenetics™

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher Announces Next-Generation Histone Peptide Array

EpiTitan™ to replace first-generation EpiGold™ Array

Chapel Hill, N.C. – August 25, 2014 – EpiCypher, a pioneer in the field of epigenetics and chromatin biology, announced today the introduction of its next-generation Histone Peptide Array – EpiTitan™. The platform was designed for rapid, high-throughput screening of effector protein interaction, antibody binding and enzyme activity. The peptides on the array encompass over 95 unique modifications on the four core histones along with several histone variants – the most available of any platform on the market.

“EpiTitan is a significant improvement over our previous platform,” said Jim Bone, President and co-founder of EpiCypher. “Some of the improvements include the capability to perform multiple experiments per array, 20 additional peptides, the ability to run two samples on one array, a significantly increased number of modifications, as well as enhanced scanning and analysis tools. This new platform will provide our customers with conclusions at critical phases of research with significantly reduced errors arising from other peptide array platforms. It also includes our patent-pending peptide spotting tracer, which significantly increases the believability of the data by reducing false negatives”.

About EpiCypher Pioneering the Science of Epigenetics™. A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells purified and recombinant nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com

EpiCypher™ Announces Epigenetic Grant Program

EpiCypher to offer five grants to researchers for histone peptide array applications that have significant impact on epigenetics research and development.

Chapel Hill, N.C. – July 1, 2014 – As part of the company’s continuing efforts to help researchers unlock biological mysteries, EpiCypher today announced they are offering five (5) fully-funded Epigenetic Grants. The company will fund projects that involve the study of the role of histone modifications in physiologic or pathologic processes. For the studies selected, EpiCypher will provide EpiTitan™ histone peptide arrays, histone modification screening services and statistical analysis of protein or antibody binding profile.

Epigenetics is the study of heritable changes in phenotype that exhibit no underlying changes in DNA sequence. Over the past several years there has been a significant increase in the number of epigenetic regulators as clinical targets, including Histone Deacetylases (HDACs), Bromodomain Proteins (BET), and histone methyltransferases including DOT1L and EZH2. A number of these targets have FDA-approved drugs, or are in late stage clinical trials, to inhibit their function, demonstrating the adoption of supporting patients with diseases involving epigenetic targets.

“Understanding fundamental questions at the molecular level are one of the most exciting and important frontiers in biomedical science, and many answers will be found through the study of chromatin biology and epigenetics. The goal of these grants is to introduce researchers to the benefits of epigenetics and to incorporate this method into their research so they can experience its biological advantages first hand,” said Jim Bone, President and co-founder of EpiCypher. “Projects should speak to the public health importance, the significance of the application and/or any clinical potential.”

Applications for the grant are due by September 10, 2014 and the awardees will be notified no later than September 29, 2014.

Media Contact: Leslie Lewis, EpiCypher, Inc. marketing@epicypher.com